MedTrace Logo

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2025-09-25

No results posted yet for this study

Summary

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Colorectal Neoplasms
  • Endometrial Neoplasms
  • Ovarian Neoplasms
  • Pancreatic Neoplasms
  • Biliary Tract Neoplasms

Interventions

DRUG

LY3537982

Oral

DRUG

Pembrolizumab

Intravenous

DRUG

Cetuximab

Intravenous

DRUG

Pemetrexed

Intravenous

DRUG

Cisplatin

Intravenous

DRUG

Carboplatin

Intravenous

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-19
Primary Completion
2027-04-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • France
  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04956640 on ClinicalTrials.gov